Glaukos is growing revenue at 41% annually, leads its peer group in growth, and carries positive price momentum with a golden cross technical setup, while analyst sentiment is constructively bullish and news flow is favorable. However, the stock is trading roughly 12% above the entry price where the risk/reward is mathematically attractive—at the current price only 4.5% separates the stock from the analyst target while potential downside is materially wider—and four high-severity revenue concentration risks alongside an expensive valuation (PEG 2.59) argue for waiting rather than chasing.
Thesis pillars
- Industry Leading Revenue Growth→Stable
- Rich Valuation Limited Margin Of Error→Stable
- Four High Severity Concentration Risks→Stable
- +2 more pillars — see the Why tab for full reasoning
Glaukos Corporation (GKOS) Stock Analysis
Healthcare · Medical Devices
Sell if holding. At $142.19, A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: U.S. customers (74.0%); Concentration risk — Product: iStent family and iDose TR glaucoma franchise (83.0%).
Glaukos develops and sells ophthalmic devices and pharmaceuticals for glaucoma, corneal disorders, and retinal disease, with 74% of 2025 net sales from U.S. customers. The glaucoma franchise — iStent devices and iDose TR — accounted for approximately 83% of net sales; iLink... Read more
Sell if holding. At $142.19, A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: U.S. customers (74.0%); Concentration risk — Product: iStent family and iDose TR glaucoma franchise (83.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 30d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Glaukos Corporation
About Glaukos Corporation
Glaukos' glaucoma franchise — the iStent family (first FDA-cleared in 2012) and the iDose TR intracameral travoprost implant (FDA-approved December 2023) — accounted for approximately 83% of 2025 net sales, with the iLink corneal cross-linking platform contributing approximately 17%. U.S. customers represented 74% of net sales in 2025 and international customers 26%, with no single customer exceeding 10% of total net sales. Epioxa, an epi-on corneal cross-linking therapy, received FDA approval in October 2025 with commercial launch planned for early 2026.
Glaukos generates revenue through a U.S. direct sales force targeting ambulatory surgery centers, hospitals, and private practices, and through direct subsidiaries and distribution partners in Australia, Brazil, Canada, Germany, Japan, and the United Kingdom. The iStent family and iDose TR are reimbursed by Medicare and major private payers; physician fee reimbursement for iDose TR continues to be standardized across Medicare Administrative Contractors via temporary CPT codes. Manufacturing for the iStent and iDose product lines is concentrated at a sole campus in San Clemente, California, and the company relies on sole-source third-party suppliers for certain device and drug components. Glaukos competes in glaucoma primarily against Alcon, AbbVie, Sight Sciences, and Iantrek, and holds the only FDA-approved bio-activated pharmaceutical for keratoconus.
Show full overview
Local coverage determinations finalized by five of seven Medicare Administrative Contractors in November 2024 confirmed non-coverage for surgical MIGS procedures performed in combination with other surgical MIGS procedures, disrupting traditional ordering patterns and potentially weighing on U.S. glaucoma revenue through 2025 and beyond. The iDose platform's longer-term trajectory depends on Phase 2b/3 trial outcomes for the second-generation iDose TREX and the Phase 3 iDose TRIO program; if those trials fail to support expanded indications, the franchise may remain confined to the first-generation travoprost implant in open-angle glaucoma and ocular hypertension.
See also: Healthcare · Medical Devices
From Glaukos Corporation's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-06-29Recent Developments — Glaukos Corporation
Latest news
- NEWS Glaukos Corp (GKOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey — TradingKey neutral
- NEWS Glaukos Corp (GKOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey — TradingKey neutral
- NEWS GKOS Maintained by Needham -- Price Target Raised to $150 - GuruFocus — GuruFocus positive
- NEWS Needham raises Glaukos stock price target on corneal treatment outlook - Investing.com UK — Investing.com UK positive
- NEWS Needham raises Glaukos stock price target on corneal treatment outlook By Investing.com - Investing.com Australia — Investing.com Australia positive
Generated 2026-06-29T23:58:56Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicU.S. customers74%10-K Item 1: 'sales to U.S. and international customers accounted for 74% and 26% of our net sales, respectively'
- HIGHProductiStent family and iDose TR glaucoma franchise83%10-K Item 1: 'our iStent family of products, iDose TR, and related glaucoma accessories accounted for approximately 83% of our net sales'
- HIGHSuppliersole manufacturing campus in San Clemente10-K Item 1A: 'Our sole manufacturing location for our iStent and iDose products is an approximately 120,000 square foot campus located in San Clemente, California'
- HIGHSuppliersole third-party component suppliers10-K Item 1A: 'we rely on a limited number of third-party suppliers, in some cases sole suppliers, to supply components for the iStent, the iStent inject models, the iStent infinite, the iDose TR'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $142.19, A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: U.S. customers (74.0%); Concentration risk — Product: iStent family and iDose TR glaucoma franchise (83.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $132.24. Score 5.4/10, moderate confidence.
Take-profit target: $142.48 (+0.2% upside). Prior stop was $132.24. Stop-loss: $132.24.
Concentration risk — Geographic: U.S. customers (74.0%); Concentration risk — Product: iStent family and iDose TR glaucoma franchise (83.0%); Analyst target reached - limited upside remaining.
Glaukos Corporation trades at a P/E of N/A (forward 325.5). TrendMatrix value score: 2.3/10. Verdict: Sell.
21 analysts cover GKOS with a consensus score of 4.2/5. Average price target: $158.
What does Glaukos Corporation do?Glaukos develops and sells ophthalmic devices and pharmaceuticals for glaucoma, corneal disorders, and retinal disease,...
Glaukos develops and sells ophthalmic devices and pharmaceuticals for glaucoma, corneal disorders, and retinal disease, with 74% of 2025 net sales from U.S. customers. The glaucoma franchise — iStent devices and iDose TR — accounted for approximately 83% of net sales; iLink corneal cross-linking therapies contributed approximately 17%. iDose TR was FDA-approved in December 2023; Epioxa, approved in October 2025, is planned for commercial launch in early 2026.